Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2

The current SARS-CoV-2 pandemic forms a major global health burden. Although protective vaccines are available, concerns remain as new virus variants continue to appear. CRISPR-based gene-editing approaches offer an attractive therapeutic strategy as the CRISPR-RNA (crRNA) can be adjusted rapidly to...

Full description

Saved in:
Bibliographic Details
Published in:Viruses Vol. 15; no. 3; p. 686
Main Authors: Hussein, Mouraya, Andrade dos Ramos, Zaria, Vink, Monique A., Kroon, Pascal, Yu, Zhenghao, Enjuanes, Luis, Zuñiga, Sonia, Berkhout, Ben, Herrera-Carrillo, Elena
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 06.03.2023
MDPI
Subjects:
Analysis
Antiviral activity
Antiviral agents
Antiviral Agents - pharmacology
Antiviral drugs
antiviral properties
Artificial chromosomes
Coronaviruses
COVID-19
COVID-19 vaccines
CRISPR
CRISPR-Cas13d
Design
Dosage and administration
FDA approval
gene editing
Gene Editing - methods
Genetic variation
Genome editing
Genomes
Genomics
Humans
Nucleotide sequence
pandemic
Pandemics
Public health
replicon
Ribonucleic acid
RNA
RNA polymerase
RNA, Viral - genetics
RNA, Viral - metabolism
SARS-CoV-2 - genetics
SARS-CoV-2 - metabolism
SARS-CoV-2 genome
Severe acute respiratory syndrome coronavirus 2
Severe acute respiratory syndrome-related coronavirus
therapeutics
viral genome
viruses
Zoonoses
Netherlands
COVID-19
CRISPR-Cas13d
RNA
SARS-CoV-2 genome
ISSN:1999-4915, 1999-4915
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current SARS-CoV-2 pandemic forms a major global health burden. Although protective vaccines are available, concerns remain as new virus variants continue to appear. CRISPR-based gene-editing approaches offer an attractive therapeutic strategy as the CRISPR-RNA (crRNA) can be adjusted rapidly to accommodate a new viral genome sequence. This study aimed at using the RNA-targeting CRISPR-Cas13d system to attack highly conserved sequences in the viral RNA genome, thereby preparing for future zoonotic outbreaks of other coronaviruses. We designed 29 crRNAs targeting highly conserved sequences along the complete SARS-CoV-2 genome. Several crRNAs demonstrated efficient silencing of a reporter with the matching viral target sequence and efficient inhibition of a SARS-CoV-2 replicon. The crRNAs that suppress SARS-CoV-2 were also able to suppress SARS-CoV, thus demonstrating the breadth of this antiviral strategy. Strikingly, we observed that only crRNAs directed against the plus-genomic RNA demonstrated antiviral activity in the replicon assay, in contrast to those that bind the minus-genomic RNA, the replication intermediate. These results point to a major difference in the vulnerability and biology of the +RNA versus −RNA strands of the SARS-CoV-2 genome and provide important insights for the design of RNA-targeting antivirals.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1999-4915
1999-4915
DOI:10.3390/v15030686